StocksMediumUpdated•Originally published 29 September 2026•Updated 29 September 2026•
1 min read
UniQure Stock Plummets 40% After Disappointing Huntington's Trial Update
Key Facts
1UniQure's Huntington's treatment showed a 44% slowing of disease progression but did not reach statistical significance in its trial.
UniQure stock plummeted 40% on Tuesday, September 29, 2026, following a disappointing four-year update for its Huntington's disease gene therapy. The clinical data showed a 44% slowing of disease progression but failed to reach the statistical significance required to prove efficacy.
Reuters reported that the gene therapy's results did not provide sufficient evidence to prove effectiveness beyond chance, a critical requirement for regulatory advancement. The failure to meet statistical thresholds in this primary pipeline candidate has severely impacted the company's valuation and future growth prospects.